Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)

Completed · Phase 3 · Has a placebo group

Conditions studied: Recurrent Vulvovaginal Candidiasis

In brief

This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of oral ibrexafungerp (formerly "SCY-078") compared to placebo in female subjects 12 years and older with recurrent VVC (RVVC).

Key facts

Study ID
NCT04029116
Run by
Scynexis, Inc.
People needed
440
Starts
2019-10-21
Expected to finish
2021-11-29
Last updated by the study team
2023-06-18

Who can join

Age: 12 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.